Seventure Partners — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsPureos BioventuresBioGeneration VenturesForbionJohnson & Johnson Innovation – JJDCBOMCurie Capital+1 more
MycoTech develops food ingredients derived from fungi using mushroom mycelial fermentation, including flavor modulation tools (ClearIQ) and a sweet protein from honey truffles for sugar reduction.
BiotechFoodTechNew MaterialsAurora, US
Alan Hahn(Executive Officer, Director, Promoter)inBrooks Kelly(Director)
BoardPeter Lubar(Director)Sanjeev Krishnan(Director)Scott Horner(Director)inEphraim Lindenbaum(Director)
Co-investorsCerity Partners VenturesGreatPoint VenturesHemisphere Ventures LLCMiddleland CapitalS2G InvestmentsTimeless Partners Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.